{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:03:21Z","timestamp":1781629401501,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Basal plasmacytosis is a histopathological hallmark of ulcerative colitis (UC). However, the precise roles of plasma cells in UC pathogenesis remain unknown. In this study, we investigated the effects of a proteasome inhibitor, which depletes plasma cells, on chronic colitis progression in mice to clarify their contribution to disease pathogenesis. Chronic colitis was induced in female C57BL\/6 mice by three cycles of ad libitum dextran sulfate sodium (DSS) feeding followed by distilled water (DW), each cycle lasting seven days. The proteasome inhibitor bortezomib was administered intravenously twice weekly for three weeks after the second DSS\/DW cycle. Elevated plasma IgG and perinuclear anti-neutrophil cytoplasmic antibody (pANCA) levels, as well as infiltration of IgG-producing plasma cells into the colon, were observed after the second DSS\/DW cycle in chronic DSS-induced colitis model mice. Plasma cells in the colon exhibited an immature CD19\u207aCD138\u207a phenotype. Bortezomib significantly ameliorated colitis and intestinal fibrosis by reducing plasma IgG and pANCA levels and the number of IgG-producing plasma cells in the colon. In conclusion, IgG-producing plasma cells were involved in colitis pathogenesis, and their depletion ameliorated colitis. Thus, IgG-producing plasma cells are associated with colitis pathogenesis and potential therapeutic targets for UC.<\/jats:p>","DOI":"10.1038\/s41598-025-34868-6","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:34:02Z","timestamp":1767886442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Depletion of IgG-producing plasma cells in the colon by treatment of proteasome inhibitor ameliorates chronic DSS-induced colitis in mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Shin","family":"Ebihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Katsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"34868_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n, F. et al. Inflammatory bowel disease (IBD), such as crohn\u2019s disease (CD) and ulcerative colitis (UC), are chronic relapsing disorders of the Gastrointestinal tract that are characterized pathologically by intestinal inflammation and epithelial injury. J. Crohns Colitis. 11, 3\u201325 (2017).","journal-title":"J. Crohns Colitis"},{"key":"34868_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","volume":"11","author":"F Magro","year":"2017","unstructured":"Magro, F. et al. Third European Evidence-based consensus on diagnosis and management of ulcerative Colitis. Part 1: Definitions, diagnosis, Extra-intestinal Manifestations, Pregnancy, cancer Surveillance, Surgery, and Ileo-anal pouch disorders. J. Crohns Colitis. 11, 649\u2013670 (2017).","journal-title":"J. Crohns Colitis"},{"key":"34868_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","volume":"14","author":"JF Colombel","year":"2020","unstructured":"Colombel, J. F., D\u2019haens, G., Lee, W. J., Petersson, J. & Panaccione, R. Outcomes and strategies to support a Treat-to-target approach in inflammatory bowel disease: A systematic review. J. Crohns Colitis. 14, 254\u2013266 (2020).","journal-title":"J. Crohns Colitis"},{"key":"34868_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh, S., George, J., Boland, B. S., Vande Casteele, N. & Sandborn, W. J. Primary Non-Response to tumor necrosis factor antagonists is associated with inferior response to Second-line biologics in patients with inflammatory bowel diseases: A systematic review and Meta-analysis. J. Crohns Colitis. 12, 635\u2013643 (2018).","journal-title":"J. Crohns Colitis"},{"key":"34868_CR5","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.crohns.2014.05.003","volume":"8","author":"V Villanacci","year":"2014","unstructured":"Villanacci, V. et al. Endoscopic biopsy samples of na\u00efve colitides patients: role of basal plasmacytosis. J. Crohns Colitis. 8, 1438\u20131443 (2014).","journal-title":"J. Crohns Colitis"},{"key":"34868_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.dld.2019.11.005","volume":"52","author":"V Villanacci","year":"2020","unstructured":"Villanacci, V. et al. Histopathology of inflammatory bowel disease - Position statement of the pathologists of the Italian group for the study of inflammatory bowel disease (IG-IBD) and Italian group of Gastrointestinal pathologists (GIPAD-SIAPEC). Dig. Liver Dis. 52, 262\u2013267 (2020).","journal-title":"Dig. Liver Dis."},{"key":"34868_CR7","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/ajg.2012.301","volume":"107","author":"T Bessissow","year":"2012","unstructured":"Bessissow, T. et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am. J. Gastroenterol. 107, 1684\u20131692 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"34868_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/gast.2001.20912","volume":"120","author":"A Bitton","year":"2001","unstructured":"Bitton, A. et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120, 13\u201320 (2001).","journal-title":"Gastroenterology"},{"key":"34868_CR9","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1093\/ibd\/izz308","volume":"26","author":"D Kevans","year":"2020","unstructured":"Kevans, D. et al. Histological markers of clinical relapse in endoscopically quiescent ulcerative colitis. Inflamm. Bowel Dis. 26, 1722\u20131729 (2020).","journal-title":"Inflamm. Bowel Dis."},{"key":"34868_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/MIB.0000000000000652","volume":"22","author":"E Zittan","year":"2016","unstructured":"Zittan, E. et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic crohn\u2019s disease. Inflamm. Bowel Dis. 22, 623\u2013630 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"34868_CR11","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3748\/wjg.v22.i3.1304","volume":"22","author":"K Mitsuyama","year":"2016","unstructured":"Mitsuyama, K. et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J. Gastroenterol. 22, 1304\u20131310 (2016).","journal-title":"World J. Gastroenterol."},{"key":"34868_CR12","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1053\/j.gastro.2021.02.019","volume":"160","author":"T Kuwada","year":"2021","unstructured":"Kuwada, T. et al. Identification of an Anti-Integrin \u03b1v\u03b26 autoantibody in patients with ulcerative colitis. Gastroenterology 160, 2383\u20132394 (2021).","journal-title":"Gastroenterology"},{"key":"34868_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.cgh.2021.12.035","volume":"21","author":"Y Kakuta","year":"2023","unstructured":"Kakuta, Y. et al. Novel diagnostic autoantibodies against endothelial protein C receptor in patients with ulcerative colitis. Clin. Gastroenterol. Hepatol. 21, 844\u2013846 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"34868_CR14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/jcmm.12728","volume":"20","author":"X Wang","year":"2016","unstructured":"Wang, X. et al. Circulating memory B cells and plasmablasts are associated with the levels of serum Immunoglobulin in patients with ulcerative colitis. J. Cell. Mol. Med. 20, 804\u2013814 (2016).","journal-title":"J. Cell. Mol. Med."},{"key":"34868_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13223-020-00433-1","volume":"16","author":"Y Pang","year":"2020","unstructured":"Pang, Y. et al. Assessment of clinical activity and severity using serum ANCA and ASCA antibodies in patients with ulcerative colitis. Allergy Asthma Clin. Immunol. 16, 37 (2020).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"34868_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/ibd.20302","volume":"4","author":"JN Gordon","year":"2008","unstructured":"Gordon, J. N. et al. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm. Bowel Dis. 4, 195\u2013203 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"34868_CR17","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1136\/gutjnl-2012-303063","volume":"62","author":"M Uo","year":"2013","unstructured":"Uo, M. et al. Mucosal CXCR4\u2009+\u2009IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through Fc\u03b3R-mediated CD14 macrophage activation. Gut 62, 1734\u20131744 (2013).","journal-title":"Gut"},{"key":"34868_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13578-019-0288-9","volume":"9","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Function and dysfunction of plasma cells in intestine. Cell. Biosci. 9, 26 (2019).","journal-title":"Cell. Biosci."},{"key":"34868_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41591-022-01680-y","volume":"28","author":"M Uzzan","year":"2022","unstructured":"Uzzan, M. et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat. Med. 28, 766\u2013779 (2022).","journal-title":"Nat. Med."},{"key":"34868_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.bbrc.2012.09.091","volume":"427","author":"K Kimura","year":"2012","unstructured":"Kimura, K. et al. Dysregulated balance of retinoid-related orphan receptor \u03b3t-dependent innate lymphoid cells is involved in the pathogenesis of chronic DSS-induced colitis. Biochem. Biophys. Res. Commun. 427, 694\u2013700 (2012).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"34868_CR21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/ecco-jcc\/jjaa015","volume":"14","author":"E Macken","year":"2020","unstructured":"Macken, E. et al. In-Depth study of transmembrane mucins in association with intestinal barrier dysfunction during the course of T cell transfer and DSS-Induced colitis. J. Crohns Colitis. 14, 974\u2013994 (2020).","journal-title":"J. Crohns Colitis"},{"key":"34868_CR22","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.3748\/wjg.v23.i33.6016","volume":"23","author":"DD Eichele","year":"2017","unstructured":"Eichele, D. D. & Kharbanda, K. K. Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our Understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol. 23, 6016\u20136029 (2017).","journal-title":"World J. Gastroenterol."},{"key":"34868_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2249.1997.291-ce1184.x","volume":"107","author":"G Kojouharoff","year":"1997","unstructured":"Kojouharoff, G. et al. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin. Exp. Immunol. 107, 353\u2013358 (1997).","journal-title":"Clin. Exp. Immunol."},{"key":"34868_CR24","doi-asserted-by":"publisher","first-page":"1179311","DOI":"10.3389\/fimmu.2023.1179311","volume":"14","author":"R Seal","year":"2023","unstructured":"Seal, R. et al. Delayed and limited administration of the JAKinib Tofacitinib mitigates chronic DSS-induced colitis. Front. Immunol. 14, 1179311 (2023).","journal-title":"Front. Immunol."},{"key":"34868_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1365-2249.2004.02402.x","volume":"136","author":"P Stopfer","year":"2004","unstructured":"Stopfer, P. et al. Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis. Clin. Exp. Immunol. 136, 21\u201329 (2004).","journal-title":"Clin. Exp. Immunol."},{"key":"34868_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","volume":"104","author":"M Ri","year":"2016","unstructured":"Ri, M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int. J. Hematol. 104, 273\u2013280 (2016).","journal-title":"Int. J. Hematol."},{"key":"34868_CR27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1158\/0008-5472.CAN-06-2258","volume":"67","author":"S Meister","year":"2007","unstructured":"Meister, S. et al. Extensive Immunoglobulin production sensitizes myeloma cells for proteasome Inhibition. Cancer Res. 67, 1783\u20131792 (2007).","journal-title":"Cancer Res."},{"key":"34868_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"12","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 12, 1630\u20131642 (2020).","journal-title":"Lancet Oncol."},{"key":"34868_CR29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748\u2013755 (2008).","journal-title":"Nat. Med."},{"key":"34868_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1681\/ASN.2010010034","volume":"22","author":"J Bontscho","year":"2011","unstructured":"Bontscho, J. et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J. Am. Soc. Nephrol. 22, 336\u2013348 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"34868_CR31","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","volume":"186","author":"AM Gomez","year":"2011","unstructured":"Gomez, A. M. et al. Proteasome Inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia Gravis. J. Immunol. 186, 2503\u20132513 (2011).","journal-title":"J. Immunol."},{"key":"34868_CR32","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander, T. et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 74, 1474\u20131478 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"34868_CR33","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/bjh.12696","volume":"164","author":"MA Mazepa","year":"2014","unstructured":"Mazepa, M. A., Raval, J. S., Moll, S., Ma, A. & Park, Y. A. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br. J. Haematol. 164, 900\u2013902 (2014).","journal-title":"Br. J. Haematol."},{"key":"34868_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1756285617721093","volume":"10","author":"C Schneider-Gold","year":"2017","unstructured":"Schneider-Gold, C., Reinacher-Schick, A., Ellrichmann, G. & Gold, R. Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience. Ther. Adv. Neurol. Disord. 10, 339\u2013341 (2017).","journal-title":"Ther. Adv. Neurol. Disord"},{"key":"34868_CR35","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","volume":"74","author":"C Zhang","year":"2017","unstructured":"Zhang, C. et al. Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis Optica spectrum disorder. JAMA Neurol. 74, 1010\u20131012 (2017).","journal-title":"JAMA Neurol."},{"key":"34868_CR36","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1053\/j.gastro.2009.07.059","volume":"137","author":"K Kobayashi","year":"2009","unstructured":"Kobayashi, K. et al. An FcRn-dependent role for anti-flagellin Immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology 137, 1746\u20131756 (2009).","journal-title":"Gastroenterology"},{"key":"34868_CR37","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.immuni.2019.02.006","volume":"50","author":"T Castro-Dopico","year":"2019","unstructured":"Castro-Dopico, T. et al. Anti-commensal IgG drives intestinal inflammation and type 17 immunity in ulcerative colitis. Immunity 50, 1099\u20131114 (2019).","journal-title":"Immunity"},{"key":"34868_CR38","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/eji.201747019","volume":"47","author":"K Pracht","year":"2017","unstructured":"Pracht, K. et al. A new staining protocol for detection of murine antibody-secreting plasma cell subsets by flow cytometry. Eur. J. Immunol. 47, 1389\u20131392 (2017).","journal-title":"Eur. J. Immunol."},{"key":"34868_CR39","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/ibd.20447","volume":"14","author":"N Hirata","year":"2008","unstructured":"Hirata, N. et al. Proliferation of immature plasma cells in pouchitis mucosa in patients with ulcerative colitis. Inflamm. Bowel Dis. 14, 1084\u20131090 (2008).","journal-title":"Inflamm. Bowel Dis."},{"key":"34868_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2249.2010.04290.x","volume":"163","author":"S Hosomi","year":"2011","unstructured":"Hosomi, S. et al. Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis. Clin. Exp. Immunol. 163, 215\u2013224 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"34868_CR41","doi-asserted-by":"publisher","first-page":"e105602","DOI":"10.1371\/journal.pone.0105602","volume":"9","author":"CA Gedye","year":"2014","unstructured":"Gedye, C. A. et al. Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneity. PLoS One. 9, e105602 (2014).","journal-title":"PLoS One"},{"key":"34868_CR42","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1136\/gut.33.7.902","volume":"33","author":"TS Halstensen","year":"1992","unstructured":"Halstensen, T. S., Mollnes, T. E., Garred, P., Fausa, O. & Brandtzaeg, P. Surface epithelium related activation of complement differs in crohn\u2019s disease and ulcerative colitis. Gut 33, 902\u2013908 (1992).","journal-title":"Gut"},{"key":"34868_CR43","first-page":"4557","volume":"7","author":"U Erben","year":"2014","unstructured":"Erben, U. et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int. J. Clin. Exp. Pathol. 7, 4557\u20134576 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"34868_CR44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1440-1827.2011.02647.x","volume":"61","author":"K Suzuki","year":"2011","unstructured":"Suzuki, K. et al. Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium. Pathol. Int. 61, 228\u2013238 (2011).","journal-title":"Pathol. Int."},{"key":"34868_CR45","doi-asserted-by":"publisher","first-page":"670159","DOI":"10.3389\/fimmu.2021.670159","volume":"12","author":"R Wang","year":"2021","unstructured":"Wang, R. et al. Therapeutic targeting of Nrf2 signaling by maggot extracts ameliorates Inflammation-Associated intestinal fibrosis in chronic DSS-Induced colitis. Front. Immunol. 12, 670159 (2021).","journal-title":"Front. Immunol."},{"key":"34868_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41385-020-0259-9","volume":"13","author":"S Zhao","year":"2020","unstructured":"Zhao, S. et al. Selective deletion of MyD88 signaling in alpha-SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation. Mucosal Immunol. 13, 665\u2013678 (2020).","journal-title":"Mucosal Immunol."},{"key":"34868_CR47","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/gut.2010.225482","volume":"60","author":"K Leiper","year":"2011","unstructured":"Leiper, K. et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 60, 1520\u20131526 (2011).","journal-title":"Gut"},{"key":"34868_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1053\/j.gastro.2011.11.009","volume":"142","author":"E Calder\u00f3n-G\u00f3mez","year":"2012","unstructured":"Calder\u00f3n-G\u00f3mez, E. & Pan\u00e9s, J. Rituximab in active ulcerative colitis. Gastroenterology 142, 174\u2013176 (2012).","journal-title":"Gastroenterology"},{"key":"34868_CR49","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1016\/j.febslet.2005.02.073","volume":"579","author":"G Kovvali","year":"2005","unstructured":"Kovvali, G. & Das, K. M. Molecular mimicry May contribute to pathogenesis of ulcerative colitis. FEBS Lett. 579, 2261\u20132266 (2005).","journal-title":"FEBS Lett."},{"key":"34868_CR50","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1128\/IAI.68.3.1542-1548.2000","volume":"68","author":"O Cohavy","year":"2000","unstructured":"Cohavy, O. et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect. Immunol. 68, 1542\u20131548 (2000).","journal-title":"Infect. Immunol."},{"key":"34868_CR51","first-page":"1419","volume":"7","author":"JB Sunwoo","year":"2001","unstructured":"Sunwoo, J. B. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7, 1419\u20131428 (2001).","journal-title":"Clin. Cancer Res."},{"key":"34868_CR52","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3164\/jcbn.18-42","volume":"63","author":"S Sakai","year":"2018","unstructured":"Sakai, S. et al. Ameliorating effects of bortezomib, a proteasome inhibitor, on development of dextran sulfate sodium-induced murine colitis. J. Clin. Biochem. Nutr. 63, 217\u2013223 (2018).","journal-title":"J. Clin. Biochem. Nutr."},{"key":"34868_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.13014","volume":"303","author":"M Bemark","year":"2021","unstructured":"Bemark, M. & Angeletti, D. Know your enemy or find your friend?-Induction of IgA at mucosal surfaces. Immunol. Rev. 303, 83\u2013102 (2021).","journal-title":"Immunol. Rev."},{"key":"34868_CR54","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/apt.14526","volume":"47","author":"IO Gordon","year":"2018","unstructured":"Gordon, I. O. et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment. Pharmacol. Ther. 47, 922\u2013939 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"34868_CR55","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/ecco-jcc\/jjv133","volume":"9","author":"JR de Bruyn","year":"2015","unstructured":"de Bruyn, J. R. et al. Development of fibrosis in acute and longstanding ulcerative colitis. J. Crohns Colitis. 9, 966\u2013972 (2015).","journal-title":"J. Crohns Colitis"},{"key":"34868_CR56","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.3390\/diagnostics13132188","volume":"13","author":"H Tavares de Sousa","year":"2023","unstructured":"Tavares de Sousa, H. & Magro, F. How to evaluate fibrosis in IBD? Diagnostics (Basel). 13, 2188 (2023).","journal-title":"Diagnostics (Basel)"},{"key":"34868_CR57","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1172\/JCI119068","volume":"98","author":"E Tony","year":"1996","unstructured":"Tony, E. et al. Intracellular demonstration of active TGFb1 in B cells and plasma cells of autoimmune mice. J. Clin. Invest. 98, 2496\u20132506 (1996).","journal-title":"J. Clin. Invest."},{"key":"34868_CR58","doi-asserted-by":"publisher","first-page":"2101469","DOI":"10.1183\/13993003.01469-2021","volume":"60","author":"CM Pr\u00eale","year":"2022","unstructured":"Pr\u00eale, C. M. et al. Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis. Eur. Respir J. 60, 2101469 (2022).","journal-title":"Eur. Respir J."},{"key":"34868_CR59","doi-asserted-by":"publisher","first-page":"e5166","DOI":"10.7717\/peerj.5166","volume":"6","author":"J Miyoshi","year":"2018","unstructured":"Miyoshi, J. et al. Minimizing confounders and increasing data quality in murine models for studies of the gut Microbiome. PeerJ 6, e5166 (2018).","journal-title":"PeerJ"},{"key":"34868_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ibd.20054","volume":"13","author":"M Ferrante","year":"2007","unstructured":"Ferrante, M. et al. Predictors of early response to Infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. 13, 123\u2013128 (2007).","journal-title":"Inflamm. Bowel Dis."},{"key":"34868_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14423\/SMJ.0000000000000253","volume":"108","author":"DL Nguyen","year":"2015","unstructured":"Nguyen, D. L., Nguyen, E. T. & Bechtold, M. L. pANCA positivity predicts lower clinical response to Infliximab therapy among patients with IBD. South. Med. J. 108, 139\u2013143 (2015).","journal-title":"South. Med. J."},{"key":"34868_CR62","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","volume":"68","author":"R Gaujoux","year":"2019","unstructured":"Gaujoux, R. et al. Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD. Gut 68, 604\u2013614 (2019).","journal-title":"Gut"},{"key":"34868_CR63","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00428-005-0136-7","volume":"448","author":"Y Jinno","year":"2006","unstructured":"Jinno, Y. et al. Infiltration of CD19\u2009+\u2009plasma cells with frequent labeling of Ki-67 in corticosteroid-resistant active ulcerative colitis. Virchows Arch. 448, 412\u2013421 (2006).","journal-title":"Virchows Arch."},{"key":"34868_CR64","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12876-023-03054-1","volume":"23","author":"S Ebihara","year":"2023","unstructured":"Ebihara, S., Urashima, T., Amano, W., Yamamura, H. & Konishi, N. Macrophage polarization toward M1 phenotype in T cell transfer colitis model. BMC Gastroenterol. 23, 411 (2023).","journal-title":"BMC Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34868-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34868-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34868-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:20:05Z","timestamp":1781626805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34868-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34868"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34868-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7646295\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experiments adhered to the ARRIVE guidelines and Guidelines for Animal Experimentation of the Central Pharmaceutical Research Institute of Japan Tobacco Inc. (Protocol No. 02950, Data: Jan 5, 2022). All animal experimental protocols were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Central Pharmaceutical Research Institute of Japan Tobacco Inc., and all procedures were conducted in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"4657"}}